company background image
LYEL

Lyell Immunopharma NasdaqGS:LYEL Stock Report

Last Price

US$3.27

Market Cap

US$815.3m

7D

7.6%

1Y

-45.3%

Updated

31 Jan, 2023

Data

Company Financials +

Lyell Immunopharma, Inc.

NasdaqGS:LYEL Stock Report

Mkt Cap: US$815.3m

LYEL Stock Overview

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors.

LYEL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Lyell Immunopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lyell Immunopharma
Historical stock prices
Current Share PriceUS$3.27
52 Week HighUS$8.74
52 Week LowUS$2.74
Beta0
1 Month Change-5.76%
3 Month Change-40.76%
1 Year Change-45.32%
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.64%

Recent News & Updates

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Dec 15
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Recent updates

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Dec 15
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Sep 12
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Aug 08
News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Apr 29
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Dec 31
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Sep 17
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Shareholder Returns

LYELUS BiotechsUS Market
7D7.6%0.8%2.8%
1Y-45.3%7.1%-9.2%

Return vs Industry: LYEL underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: LYEL underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is LYEL's price volatile compared to industry and market?
LYEL volatility
LYEL Average Weekly Movement10.8%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: LYEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: LYEL's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018219Lynn Seelyhttps://www.lyell.com

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications.

Lyell Immunopharma, Inc. Fundamentals Summary

How do Lyell Immunopharma's earnings and revenue compare to its market cap?
LYEL fundamental statistics
Market CapUS$815.29m
Earnings (TTM)-US$258.43m
Revenue (TTM)US$39.12m

20.8x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LYEL income statement (TTM)
RevenueUS$39.12m
Cost of RevenueUS$0
Gross ProfitUS$39.12m
Other ExpensesUS$297.55m
Earnings-US$258.43m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.04
Gross Margin100.00%
Net Profit Margin-660.62%
Debt/Equity Ratio0%

How did LYEL perform over the long term?

See historical performance and comparison